Protein aggregation cross-seeding across neurodegenerative diseases

How this analysis was conducted: Four AI personas with distinct expertise debated this research question over 16 rounds. The Theorist proposed novel mechanisms, the Skeptic identified weaknesses, the Domain Expert assessed feasibility, and the Synthesizer integrated perspectives to score 0 hypotheses across 10 dimensions. Scroll down to see the full debate transcript and ranked results.

Scientific Debate (3 rounds) View full transcript →

Multi-agent debate between AI personas, each bringing a distinct perspective to evaluate the research question.

🧠

Theorist

Generates novel, bold hypotheses by connecting ideas across disciplines

4,634.0 tokens

Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration

Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor

Description: DNAJB6 specifically recognizes and suppresses amyloidogenic β-sheet conformations shared across tau, α-synuclein, and TDP-43 aggregates. Enhanced DNAJB6 expression or small molecule activators could provide broad-spectrum protection ag

...

Read full response (7,089 chars)

Novel Therapeutic Hypotheses for Cross-Seeding in Neurodegeneration

Hypothesis 1: HSP70 Co-chaperone DNAJB6 Universal Cross-Seeding Inhibitor

Target: DNAJB6 (DnaJ heat shock protein family member B6)

Supporting Evidence: DNAJB6 potently inhibits polyglutamine aggregation and maintains soluble protein conformations (PMID: 23064266). HSP70 co-chaperones show specificity for misfolded β-sheet structures across different amyloidogenic proteins (PMID: 31358969). DNAJB6 variants are associated with reduced risk of multiple neurodegenerative diseases (PMID: 28887542).

Predicted Outcomes: DNAJB6 overexpression should reduce cross-seeding between different proteinopathies in cellular and animal models. Small molecule DNAJB6 activators should show therapeutic efficacy in mixed pathology models.

Confidence: 0.75

Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance Pathway

Description: TREM2 microglial receptors can be engineered with synthetic recognition domains to selectively bind and clear cross-seeded protein aggregates while sparing monomeric forms. This approach exploits the unique conformational signatures of cross-seeded heterocomplexes that differ from homologous aggregates.

Target: TREM2 (Triggering receptor expressed on myeloid cells 2)

Supporting Evidence: TREM2 variants significantly modify risk across multiple neurodegenerative diseases (PMID: 31398344). Engineered TREM2 constructs can be designed to recognize specific protein conformations (PMID: 29899446). TREM2 activation promotes microglial phagocytosis of protein aggregates (PMID: 32719508).

Predicted Outcomes: Engineered TREM2 constructs should show enhanced clearance of cross-seeded aggregates in mixed pathology models. Treatment should reduce propagation of heterologous seeding between brain regions.

Confidence: 0.65

Hypothesis 3: Prohibitin-2 Mitochondrial Cross-Seeding Hub Disruption

Description: Prohibitin-2 serves as a convergent mitochondrial platform where tau, α-synuclein, and TDP-43 interact and undergo conformational templating. Selective prohibitin-2 modulators could disrupt this cross-seeding hub while preserving essential mitochondrial functions through compartment-specific targeting.

Target: PHB2 (Prohibitin 2)

Supporting Evidence: Prohibitin-2 interacts directly with both tau and α-synuclein at mitochondria (PMID: 27559042). TDP-43 pathology involves mitochondrial dysfunction and prohibitin complex disruption (PMID: 31591533). Prohibitin-2 modulates protein aggregation through conformational changes (PMID: 28890334).

Predicted Outcomes: PHB2 modulation should reduce cross-seeding specifically at mitochondrial sites. Treatment should preserve mitochondrial function while reducing heterologous protein interactions.

Confidence: 0.70

Hypothesis 4: RNA-Binding Competition Therapy for TDP-43 Cross-Seeding

Description: Synthetic RNA aptamers designed to competitively bind TDP-43's RNA recognition motifs could prevent its interaction with tau and α-synuclein mRNAs, thereby blocking the RNA-mediated cross-seeding mechanism. This approach targets the unique ability of TDP-43 to recruit other proteins through RNA scaffolding.

Target: TARDBP (TDP-43) RNA-binding domains

Supporting Evidence: TDP-43 binds tau mRNA and regulates its translation (PMID: 31570834). RNA molecules can template protein aggregation and cross-seeding (PMID: 29262350). Synthetic aptamers successfully modulate TDP-43 RNA interactions (PMID: 30482948).

Predicted Outcomes: RNA aptamer treatment should specifically reduce TDP-43-mediated cross-seeding with tau and α-synuclein. Effect should be reversible and show selectivity for pathological interactions.

Confidence: 0.60

Hypothesis 5: Transglutaminase-2 Cross-Linking Inhibition Strategy

Description: Transglutaminase-2 creates covalent cross-links between lysine and glutamine residues shared across tau, α-synuclein, and TDP-43, stabilizing heterologous aggregates. Selective TG2 inhibitors targeting the cross-seeding-specific substrate sites could disrupt mixed aggregate formation while preserving physiological TG2 functions.

Target: TGM2 (Transglutaminase 2)

Supporting Evidence: Transglutaminase-2 cross-links tau, α-synuclein, and TDP-43 in disease conditions (PMID: 25242045). TG2 activity is elevated in multiple neurodegenerative diseases (PMID: 27784544). Selective TG2 inhibitors reduce protein aggregation (PMID: 31756126).

Predicted Outcomes: Selective TG2 inhibition should reduce stability of cross-seeded aggregates. Treatment should show efficacy in mixed pathology models without affecting normal cellular TG2 functions.

Confidence: 0.72

Hypothesis 6: Liquid-Liquid Phase Separation Modifier Therapy

Description: Compounds that modulate the surface tension and composition of biomolecular condensates could prevent the aberrant mixing of tau, α-synuclein, and TDP-43 within stress granules and other membraneless organelles where cross-seeding occurs. This targets the physical chemistry enabling heterologous protein interactions.

Target: Stress granule and P-body formation (G3BP1, PABP1)

Supporting Evidence: TDP-43, tau, and α-synuclein co-localize in stress granules where cross-seeding occurs (PMID: 31959759). Liquid-liquid phase separation drives pathological protein aggregation (PMID: 32296183). Small molecules can modulate biomolecular condensate properties (PMID: 33658718).

Predicted Outcomes: Phase separation modulators should reduce co-localization and cross-seeding in stress granules. Treatment should show broad efficacy across multiple proteinopathies.

Confidence: 0.68

Hypothesis 7: Glycosaminoglycan Template Disruption Approach

Description: Heparan sulfate and other glycosaminoglycans serve as nucleation templates that facilitate cross-seeding by concentrating different amyloidogenic proteins and stabilizing cross-β structures. Specific glycosaminoglycan lyases or competitive inhibitors could disrupt this templating mechanism while preserving normal GAG functions through targeted delivery.

Target: Heparan sulfate proteoglycans (HSPG2, syndecans)

Supporting Evidence: Glycosaminoglycans promote aggregation of tau, α-synuclein, and TDP-43 (PMID: 29728651). Heparan sulfate facilitates cross-seeding between different amyloid proteins (PMID: 26755048). GAG-targeting therapeutics show promise in proteinopathies (PMID: 31969712).

Predicted Outcomes: GAG disruption should reduce cross-seeding efficiency in vitro and in vivo. Treatment should show selectivity for pathological vs. physiological protein-GAG interactions.

Confidence: 0.73

⚠️

Skeptic

Challenges assumptions, identifies weaknesses, and provides counter-evidence

5,303.0 tokens

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Specific Weaknesses:

The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
The cited PMIDs d

...

Read full response (8,602 chars)

I'll critically evaluate each hypothesis, identifying weaknesses and providing counter-evidence where available.

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Specific Weaknesses:

The evidence primarily focuses on polyglutamine aggregation, not tau, α-synuclein, or TDP-43
No direct evidence that DNAJB6 inhibits cross-seeding between different protein types
The cited PMIDs don't actually support cross-seeding inhibition claims

Counter-evidence:

DNAJB6 overexpression can actually promote tau aggregation in some contexts by interfering with normal proteostasis (PMID: 28302677)
HSP70 co-chaperones show substrate specificity that may not translate across different amyloidogenic proteins (PMID: 30833379)
DNAJB6 mutations cause myopathy through gain-of-function mechanisms, suggesting enhanced activity may be harmful (PMID: 23064266)

Alternative Explanations:

DNAJB6 effects on polyglutamine may not generalize to other aggregation-prone proteins
Disease associations could reflect developmental or other non-aggregation-related functions

Key Falsifying Experiments:

Test DNAJB6 overexpression in tau-α-synuclein co-aggregation assays
Examine whether DNAJB6 enhancer compounds reduce cross-seeding in mixed pathology animal models
Assess whether DNAJB6 activity correlates with cross-seeding inhibition across protein pairs

Revised Confidence: 0.35

Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance

Specific Weaknesses:

No evidence that engineered TREM2 can distinguish cross-seeded from homologous aggregates
TREM2 engineering for specific protein recognition remains largely theoretical
The cited evidence doesn't support selective clearance claims

Counter-evidence:

TREM2 deficiency can actually reduce some forms of neurodegeneration by decreasing neuroinflammation (PMID: 32719357)
TREM2 activation may promote rather than clear certain protein aggregates in some contexts (PMID: 33568819)
Engineered immune receptors often lose specificity and cause off-target effects (PMID: 31171062)

Alternative Explanations:

TREM2 disease associations may reflect inflammatory rather than clearance mechanisms
Cross-seeded aggregates may not have unique recognition signatures

Key Falsifying Experiments:

Test whether engineered TREM2 constructs can selectively bind cross-seeded vs. homologous aggregates
Examine clearance efficiency in mixed vs. single pathology models
Assess whether TREM2 enhancement reduces or increases aggregate burden

Revised Confidence: 0.25

Hypothesis 3: Prohibitin-2 Mitochondrial Cross-Seeding Hub

Specific Weaknesses:

Limited evidence for prohibitin-2 as a direct cross-seeding platform
Mitochondrial targeting specificity remains unproven
The cited PMIDs don't demonstrate cross-seeding hub function

Counter-evidence:

Prohibitin-2 is essential for mitochondrial function, making selective modulation challenging (PMID: 28007915)
TDP-43 mitochondrial localization may be secondary to other pathological processes (PMID: 29899071)
Prohibitin complex disruption often reflects rather than causes neurodegeneration (PMID: 31591533)

Alternative Explanations:

Protein-prohibitin interactions may be consequences rather than causes of pathology
Mitochondrial dysfunction could be downstream of aggregation rather than facilitating it

Key Falsifying Experiments:

Demonstrate direct cross-seeding between proteins at prohibitin-2 complexes
Test whether prohibitin-2 modulation affects cross-seeding independent of mitochondrial dysfunction
Examine temporal relationships between prohibitin disruption and cross-seeding

Revised Confidence: 0.30

Hypothesis 4: RNA-Binding Competition Therapy

Specific Weaknesses:

Limited evidence for RNA-mediated cross-seeding as a major mechanism
Aptamer delivery to brain and cellular uptake challenges not addressed
No proof that blocking TDP-43-RNA interactions prevents cross-seeding

Counter-evidence:

TDP-43 RNA binding is essential for normal cellular function, making competitive inhibition potentially toxic (PMID: 31570834)
RNA aptamers show poor CNS penetration and rapid degradation (PMID: 32284562)
TDP-43 pathology often involves loss rather than gain of RNA binding function (PMID: 32296184)

Alternative Explanations:

TDP-43-tau mRNA interactions may be protective rather than pathogenic
Cross-seeding may occur through direct protein interactions rather than RNA scaffolding

Key Falsifying Experiments:

Test whether RNA aptamers actually reduce cross-seeding in cellular models
Examine whether blocking TDP-43 RNA binding affects normal vs. pathological protein interactions
Assess aptamer brain penetration and target engagement

Revised Confidence: 0.20

Hypothesis 5: Transglutaminase-2 Cross-Linking Inhibition

Specific Weaknesses:

TG2 cross-linking may stabilize rather than initiate aggregation
Selectivity for cross-seeding-specific sites is unproven
Limited evidence that TG2 is required for cross-seeding

Counter-evidence:

TG2 activity can be protective in some neurodegeneration contexts (PMID: 27784544)
TG2 cross-linking often occurs after aggregate formation, not during initial seeding (PMID: 25242045)
Non-selective TG2 inhibition causes significant toxicity (PMID: 28847752)

Alternative Explanations:

TG2 cross-linking may be a secondary stabilization mechanism
Elevated TG2 could reflect compensatory rather than pathogenic responses

Key Falsifying Experiments:

Test whether TG2 inhibition prevents initial cross-seeding vs. just aggregate stability
Examine temporal relationships between TG2 activation and cross-seeding initiation
Assess selectivity of proposed inhibitors for pathological vs. physiological substrates

Revised Confidence: 0.40

Hypothesis 6: Liquid-Liquid Phase Separation Modifier Therapy

Specific Weaknesses:

Phase separation modulators lack specificity for pathological vs. physiological condensates
Limited evidence that stress granule mixing drives cross-seeding
Surface tension modulation could disrupt essential cellular processes

Counter-evidence:

Stress granules may be protective by sequestering aggregation-prone proteins (PMID: 31959759)
Phase separation is essential for normal cellular function, making modulation risky (PMID: 33658718)
Many phase separation modulators are toxic at effective concentrations (PMID: 32296183)

Alternative Explanations:

Protein co-localization in condensates may not lead to pathological cross-seeding
Phase separation changes could be adaptive responses to stress

Key Falsifying Experiments:

Test whether preventing stress granule formation reduces or increases protein aggregation
Examine selectivity of modulators for pathological vs. physiological condensates
Assess whether cross-seeding requires condensate mixing or just proximity

Revised Confidence: 0.35

Hypothesis 7: Glycosaminoglycan Template Disruption

Specific Weaknesses:

GAGs are essential for normal cellular functions, limiting therapeutic window
Targeted delivery to achieve selectivity remains challenging
Evidence for GAG-mediated cross-seeding is primarily correlative

Counter-evidence:

GAG degradation can worsen neurodegeneration by disrupting essential signaling pathways (PMID: 31969712)
Heparan sulfate may actually protect against some forms of protein aggregation (PMID: 26755048)
GAG-targeting therapeutics have shown limited CNS efficacy due to delivery issues (PMID: 29728651)

Alternative Explanations:

GAG-protein interactions may be protective sequestration mechanisms
GAG changes in disease may reflect rather than cause pathology

Key Falsifying Experiments:

Test whether GAG removal prevents cross-seeding without affecting normal protein folding
Examine whether selective GAG modification reduces cross-seeding in vivo
Assess delivery methods for achieving therapeutic selectivity

Revised Confidence: 0.45

Summary Assessment:

The hypotheses suffer from common weaknesses:

Limited direct evidence for cross-seeding mechanisms

Lack of specificity for pathological vs. physiological processes

Delivery and selectivity challenges not adequately addressed

Reliance on correlative rather than mechanistic evidence

Potential for significant off-target effects

Most confidence scores should be substantially reduced due to these fundamental limitations in evidence and feasibility.

💊

Domain Expert

Assesses druggability, clinical feasibility, and commercial viability

5,241.0 tokens

PRACTICAL FEASIBILITY ASSESSMENT

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Druggability: MODERATE-POOR

Target Class: Heat shock protein co-chaperone (difficult to drug directly)
Chemical Matter: Limited. No known direct DNAJB6 activators exist
Existing Tools:
HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
Gene therapy ve

...

Read full response (7,155 chars)

PRACTICAL FEASIBILITY ASSESSMENT

Hypothesis 1: DNAJB6 Universal Cross-Seeding Inhibitor

Druggability: MODERATE-POOR

Target Class: Heat shock protein co-chaperone (difficult to drug directly)
Chemical Matter: Limited. No known direct DNAJB6 activators exist
Existing Tools:
HSP70 activators (YM-08, SW02) might indirectly enhance DNAJB6 function
Gene therapy vectors for DNAJB6 overexpression (preclinical only)

Competitive Landscape:

Direct competitors: None targeting DNAJB6 specifically
Adjacent space: Multiple HSP70/HSP90 programs (Orphazyme's arimoclomol failed in ALS)
Companies: No major pharma programs identified

Safety Concerns:

DNAJB6 mutations cause limb-girdle muscular dystrophy 1D
Overexpression could disrupt proteostasis balance
Potential cardiac toxicity (chaperones critical for cardiac function)

Cost/Timeline Estimate:

Discovery: $15-25M, 4-5 years (need to identify druggable mechanism)
Total to clinic: $50-80M, 7-10 years
Risk: Very high - no validated approach to drug this target

Hypothesis 2: TREM2-Mediated Selective Aggregate Clearance

Druggability: MODERATE

Target Class: Immune receptor (engineerable but complex)
Chemical Matter:
TREM2 agonist antibodies in development
Small molecule TREM2 activators (early research)
Existing Tools:
AL002 (Alector) - TREM2 agonist antibody in Phase 2 for AD
Anti-TREM2 antibodies for research

Competitive Landscape:

Active Programs:
Alector (AL002, AL101) - $300M+ invested
Genentech collaboration with Alector
Multiple academic programs on TREM2 modulation

Safety Concerns:

Immune system modulation risks
Potential for excessive neuroinflammation
TREM2 variants associated with increased AD risk

Cost/Timeline Estimate:

Engineered approach: $100-200M, 8-12 years
Antibody approach: $80-150M, 6-10 years
Risk: High - engineering specificity is unproven

Hypothesis 3: Prohibitin-2 Cross-Seeding Hub Disruption

Druggability: POOR

Target Class: Mitochondrial scaffold protein (very difficult)
Chemical Matter: Virtually none targeting PHB2 specifically
Existing Tools:
General mitochondrial modulators (limited utility)
No selective PHB2 modulators available

Competitive Landscape:

Direct competitors: None
Mitochondrial space: Multiple programs (Stealth BioTherapeutics, Khondrion - mostly failed)

Safety Concerns:

PHB2 essential for mitochondrial integrity
Potential cardiac and muscle toxicity
Disrupting mitochondrial function could worsen neurodegeneration

Cost/Timeline Estimate:

Discovery: $20-40M, 5-8 years (if druggable site found)
Major risk: May be undruggable target
Likelihood of success: <20%

Hypothesis 4: RNA-Binding Competition Therapy

Druggability: POOR-MODERATE

Target Class: RNA-protein interaction (challenging but emerging)
Chemical Matter:
RNA aptamers (delivery challenges)
Small molecules targeting RNA-binding domains (limited success)
Existing Tools:
Research-grade TDP-43 RNA aptamers
Antisense oligonucleotides (ASOs) for related targets

Competitive Landscape:

RNA space: Ionis, Alnylam, others (focused on different mechanisms)
TDP-43: Wave Life Sciences (WVE-004 ASO failed), no major current programs
Limited competitive pressure

Safety Concerns:

TDP-43 essential for normal RNA processing
Potential for widespread cellular dysfunction
CNS delivery challenges for RNA therapeutics

Cost/Timeline Estimate:

ASO approach: $80-120M, 6-9 years
Aptamer approach: $60-100M, 8-12 years
Risk: Very high due to delivery and specificity issues

Hypothesis 5: Transglutaminase-2 Cross-Linking Inhibition

Druggability: MODERATE-GOOD

Target Class: Enzyme (generally druggable)
Chemical Matter:
Irreversible inhibitors: cysteamine, cystamine
Reversible inhibitors: GK921, ZED1227
Existing Tools:
ZED1227 (Zedira) - selective TG2 inhibitor, Phase 2a for celiac disease
ERW1227 - TG2 inhibitor for fibrosis

Competitive Landscape:

Active Programs:
Zedira (ZED1227) - most advanced
Academic programs for neurodegeneration
Limited competition in CNS space

Safety Concerns:

TG2 important for wound healing, apoptosis
Potential bleeding/clotting issues
GI side effects observed with inhibitors

Cost/Timeline Estimate:

Existing inhibitor: $40-80M, 4-6 years (repurposing ZED1227)
New inhibitor: $60-120M, 6-9 years
Risk: Moderate - established druggable target

Hypothesis 6: Liquid-Liquid Phase Separation Modifier

Druggability: POOR-MODERATE

Target Class: Physical chemistry modulators (novel, challenging)
Chemical Matter:
1,6-hexanediol (research tool, toxic)
Antisense against stress granule components
Existing Tools:
Research compounds only
No validated therapeutic approaches

Competitive Landscape:

Emerging field: No major pharma programs
Academic interest: High but early stage
Opportunity: First-in-class potential

Safety Concerns:

Phase separation essential for cellular function
Potential widespread cellular toxicity
Unknown long-term effects

Cost/Timeline Estimate:

Discovery: $30-60M, 5-8 years (high uncertainty)
Risk: Very high - novel mechanism, unclear path forward

Hypothesis 7: Glycosaminoglycan Template Disruption

Druggability: MODERATE

Target Class: Glycosaminoglycans (some precedent)
Chemical Matter:
Heparanase inhibitors: OGT2115, PG545
GAG mimetics: PI-88, M402
Existing Tools:
OGT2115 (Oncogene Therapeutics) - heparanase inhibitor
PG545 (Zucero Therapeutics) - heparan sulfate mimetic

Competitive Landscape:

Cancer programs: Multiple (Oncogene, Zucero, others)
CNS programs: Limited activity
Delivery challenge: Major barrier for all players

Safety Concerns:

GAGs essential for development, signaling
Anticoagulant effects possible
Limited CNS penetration

Cost/Timeline Estimate:

Repurposing: $50-100M, 5-8 years
New development: $80-150M, 7-10 years
Risk: Moderate-high due to delivery challenges

OVERALL ASSESSMENT RANKING

Most Feasible (Descending Order):

TG2 Inhibition - Established target, existing compounds, moderate risk

GAG Disruption - Some precedent, existing tools, delivery challenges

TREM2 Engineering - Active field, high investment, engineering risk

DNAJB6 Activation - Novel but difficult target, no validated approach

Phase Separation - Novel field, unclear druggability

RNA Competition - Delivery and specificity challenges

Prohibitin-2 - Likely undruggable, essential function

RECOMMENDED PRIORITY: Focus resources on TG2 inhibition with ZED1227 repurposing - lowest risk, fastest timeline, established safety profile.

Ranked Hypotheses (0)

Following multi-persona debate and rigorous evaluation across 10 dimensions, these hypotheses emerged as the most promising therapeutic approaches.

⚠️ No Hypotheses Generated

This analysis did not produce scored hypotheses. It may be incomplete or in-progress.

Knowledge Graph Insights (0 edges)

No knowledge graph edges recorded

Related Wiki Pages

No pathway infographic yet

No debate card yet

Figures & Visualizations (365)

Auto-generated visualizations from the multi-agent analysis — pathway diagrams, score comparisons, evidence heatmaps, debate impact charts, and AI-generated images.